Skip to Main Content

Paper Details

The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
Cancer Res
168
2015
ATPase, ATPase domain, GFP, PFI-3, SMARCA2, SMARCA2-bromodomain, SMARCA2/4, SMARCA2/4 ATPase Domain, SMARCA2/4 bromodomain, SMARCA4, SMARCA4-deficient lung cancer, SNF, SWI, SWI/SNF-Mutant Cancers, SWI/SNF-mutant tumors, anticancer, bromodomain, bromodomain- and ATPase-dead constructs, cDNA, cancer, cancer cells, chromatin, full-length SMARCA2, helicase, leukemia, rhabdoid tumors, synovial sarcoma, target gene
Author NameAffiliation
Maria Kost-AlimovaInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center
Harshad S MahadeshwarInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center
Harshad S MahadeshwarInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center
Alexei ProtopopovInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center
Alexei ProtopopovInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center
Phillip A FutrealThe University of Texas MD Anderson Cancer Center
Timothy P HeffernanInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center
  • 1 - 7

Datasets

Release 1.2